HLA-Incompatible Kidney Transplantation — Worth the Risk?

Lionel P.E. Rostaing, M.D., Ph.D., and Paolo Malvezzi, M.D.

N Engl J Med 2016; 374:982-984March 10, 2016DOI: 10.1056/NEJMe1601379

This article has no abstract; the first 100 words appear below.

Chronic kidney diseases are a major worldwide societal burden. In the United States, where the prevalence of chronic kidney disease is approximately 14%,1 close to 1 million persons have end-stage renal disease (ESRD). Of those affected, 700,000 (70.8%) are treated with dialysis, and the remaining 300,000 (29.2%) with kidney transplantation (i.e., 56 cases per 1 million population).2Currently, just over 100,000 U.S. patients with ESRD are on the waiting list for a kidney transplant, but every year, only 15 to 16% will receive a kidney transplant, and of those kidneys, 32 to 34% are from live donors.3 Annual U.S. expenditures . . .

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

SOURCE INFORMATION

From Clinique de Néphrologie, Unité de Transplantation Rénale, Centre Hospitalier Universitaire (CHU) Grenoble-Alpes, La Tronche (L.P.E.R., P.M.), and INSERM Unité 563, Federative Structure of Bio-Medical Research of Toulouse, CHU Purpan, and Université Toulouse III Paul Sabatier, Toulouse (L.P.E.R.) — all in France.